New trial
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
- Trial ID
- NCT06963346 on ClinicalTrials.gov
- Cancer type
- Bladder Cancer
- Published in
- New in Oncology - May 21, 2025
This trial explores a neoadjuvant combo of intravesical romidepsin and durvalumab in cisplatin-ineligible, muscle-invasive bladder cancer patients, testing escalating doses of the HDAC inhibitor to boost immunotherapy responses in a localized setting.
More in bladder and urothelial cancer
-
Trial result · Oct 15, 2026 · NCT04179162
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC -
Trial result · Oct 15, 2026 · NCT02773849
TAR-200 (intravesical gemcitabine device) vs nadofaragene firadenovec: no statistically significant CR durability difference detected through 24 months in BCG-unresponsive CIS -
New trial · Oct 15, 2026 · NCT07827612
Phase 2 FORAY tests selective FGFR3 inhibition with vepugratinib in low-grade bladder and upper tract urothelial tumors -
New trial · Oct 8, 2026 · NCT07815665
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC -
New trial · Oct 8, 2026 · NCT07822373
Phase 2 enfortumab vedotin Nectin-4 ADC (MMAE tubulin payload) plus pembrolizumab PD-1 antibody